Pharmaceutical Executive-11-01-2013

Pharm Exec convenes a diverse panel of experts to identify the key markers of common ground: its time, people, and money against that greatest intangible-hope.

Across a constellation of categories, bright new drugs are moving into position. The pharma model may have changed, but companies are keeping their blockbusters.

High prices, murky financial relations, and a reluctance to disclose clinical data undermine public trust in industry and the research enterprise.

The US and Europe are moving toward the enactment of new legislation that will change the way pharma products are handled and shipped throughout the supply chain.

At the conclusion of the Cleveland Clinic's Medical Innovations Summit each year, 10 innovative technologies are unveiled before the audience, and designated as new and revolutionary tools for the treatment of disease and disability.

The past three years have been some of the most eventful in memory for Taiwan's life sciences industry. At this year's Bio Taiwan exhibition, the annual conference that invites the international life sciences community to the island, the excitement was palpable. Foreign companies turned out in record numbers to a keynote address from President Ma Ying-Jeou, who acknowledged that Taiwan was a latecomer to the sector, but nonetheless had the capability and will to compete. Buoyed by a successful wave of financing, good product strategy, and increasing international penetration, the industry seems confident.

Pharm Exec's two key features this month illustrate the strategic contradiction facing today's industry.